Home >> Industry News >> DiaSorin gets EUA for Liaison SARS-CoV-2 Ag

DiaSorin gets EUA for Liaison SARS-CoV-2 Ag

image_pdfCreate PDF

In clinical studies the test showed a 97 percent sensitivity within 10 days post onset of symptoms and a 100 percent specificity on anterior nasal swabs, and a 96.1 percent sensitivity and a 99.3 percent specificity on nasopharyngeal swabs.

The Liaison SARS-CoV-2 Ag runs on the company’s Liaison XL platform.

CAP TODAY
X